BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1703989)

  • 1. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
    Pangburn MK
    Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
    Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
    Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
    Ezzell JL; Parker CJ
    Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
    Fischer E; Kazatchkine MD
    J Immunol; 1983 Jun; 130(6):2821-4. PubMed ID: 6222117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decay acceleration of the complement alternative pathway C3 convertase.
    Hourcade DE; Mitchell LM; Medof ME
    Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species specificity of recognition by the alternative pathway of complement.
    Horstmann RD; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1985 Feb; 134(2):1101-4. PubMed ID: 3155536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitory effect of factor J on the alternative complement pathway.
    González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
    J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
    Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
    J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure/function studies of human decay-accelerating factor.
    Brodbeck WG; Kuttner-Kondo L; Mold C; Medof ME
    Immunology; 2000 Sep; 101(1):104-11. PubMed ID: 11012760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.